Date: Saturday, May 2, 2015
Session Name: Poster Session A: Liver Transplantation: Viral Hepatitis
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Exhibit Hall E
Background: Interferon (IFN) free HCV regimens are associated with better tolerability and efficacy. The majority of studies report biochemical and virological response; however limited information has been published on histologic findings. Aim: Report histologic findings following sustained virological response (SVR) in LT patients (pts). Methods: HCV treatment was started between 12/2013 and 5/2014 on pts who underwent LT between 1990 and 2014. Sofosbuvir (SOF) started in all 17 pts, 8 pts treated with SOF and Ribavirin (RBV), 2 pts SOF/RBV switched to SOF and Simeprevir (SIM), 6 pts treated with SOF/SIM and one with SOF/RBV/IFN (co-infection with HIV). All but 1 pt was on tacrolimus.
|Mean age (range)||64 (53-80)|
|Mean AST (range)||54 (12-172) U/L|
|Mean ALT (range)||59 (9-166) U/L|
|Mean prior to treatment RNA level (range)||29.6 (1.24 105.9) x10 5 IU/mL|
|HCV Genotype||1a (11 patients), 1a or 1b (2), 1b (1), 2b (1), 3 (2)|
|Cirrhosis prior to treatment||5 patients|
To cite this abstract in AMA style:Ismail B, Zervos X, Bejarano P, Waton M, Beltran D, Sears D, Tzakis A. End of Treatment Liver Biopsy With Sofosbuvir: Histologic Changes Suggestive of Hepatitis C Activity in Liver Transplant Recipients With Achieved SVR [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/end-of-treatment-liver-biopsy-with-sofosbuvir-histologic-changes-suggestive-of-hepatitis-c-activity-in-liver-transplant-recipients-with-achieved-svr/. Accessed July 19, 2018.
« Back to 2015 American Transplant Congress